Upadacitinib has shown long-term benefits in teenagers with atopic dermatitis. The treatment appears to be safe and effective for this patient group over an extended period, although the exact duration is not consistently reported. Some studies also explore alternative treatments and compare upadacitinib to other options, such as dupilumab, but the focus of the current reports is on upadacitinib's long-term effects in adolescents with atopic dermatitis.